What is Merrimack Pharmaceuticals' stock symbol?
Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."
Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?
6 equities research analysts have issued 1 year price objectives for Merrimack Pharmaceuticals' shares. Their forecasts range from $5.00 to $13.00. On average, they expect Merrimack Pharmaceuticals' stock price to reach $9.50 in the next year.
When will Merrimack Pharmaceuticals announce their earnings?
Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.
What are analysts saying about Merrimack Pharmaceuticals stock?
Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:
According to Zacks Investment Research, "Merrimack achieved a major boost with the FDA approval of Onivyde. Initial uptake of the drug has been encouraging and should boost the top line, going forward. Inclusion of the drug in the National Comprehensive Cancer Network (NCCN) pathway should also drive the drug’s sales. We are also positive on the company’s efforts to expand Onivyde’s label. Moreover, Merrimack’s collaboration with Shire for Onivyde is both financially and strategically beneficial. However, we are concerned by the company's sole dependence on Onivyde for growth. Also, Merrimack undertook a restructuring move to prioritize its R&D expenses on a focused set of oncology products and to strengthen its cash runway, which led to a 22% reduction in the headcount. Estimates have been mixed lately ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (10/19/2016)
J P Morgan Chase & Co analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)
Who owns Merrimack Pharmaceuticals stock?
Merrimack Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (4.13%), Franklin Resources Inc. (3.06%), Indus Capital Partners LLC (0.81%), Guggenheim Capital LLC (0.22%) and Brown Advisory Inc. (0.16%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Edward J Stewart, Gordon J Fehr, Michael E Porter, Robert J Mulroy, Ulrik B Nielsen, Vivian S Lee, William A Sullivan and William M Mcclements.
Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?
Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., Private Advisor Group LLC, Princeton Portfolio Strategies Group LLC and Metropolitan Life Insurance Co. NY.
Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?
Merrimack Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., State Street Corp, Indus Capital Partners LLC, Guggenheim Capital LLC, ING Groep NV, FMR LLC, Perceptive Advisors LLC and Tudor Investment Corp Et Al. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements.
How do I buy Merrimack Pharmaceuticals stock?
Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Merrimack Pharmaceuticals stock cost?
One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $3.10.